Welcome to our press page, where you can find the latest news, press releases, and media resources to stay informed about our company’s developments and initiatives.
Bionity.com is the leading portal for Life Sciences and Pharma in the key markets of Europe, the USA, and Asia with over 2.6 million users. The website reported about the new partnership between CELLphenomics and Kyan Therapeutics and wrote, that the „two unique technologies will allow reliable conclusions about the treatability of the tumor and its functional causes of therapeutic success and/or failure, leading to novel treatment combinations and faster preclinical development of new anti-cancer drugs.“
Precision Medicine Online
The website precisionmedicineonline.com, published by Genome Web, reports on the new partnership between Indivumed and Cellphenomics, and discusses how both companies are collaborating on cancer drug research. The partnership promises significant advancement in cancer research, as it allows both companies to combine their expertise and resources to explore innovative approaches to cancer drug development
Transkript.de reports about the new partnership of CELLphenomics and KYAN Therapeutics. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry.
CELLphenomics and Charles River announce agreement, expanding 3D in vitro services for cancer therapy drug screening
CELLphenomics, KYAN Technologies and Alentis Therapeutics join forces
New publication in Molecular Cancer
Kyan Therapeutics and CELLphenomics announce new partnership
Indivumed and CELLphenomics announce their new partnership
You have questions, would like to learn more about CELLphenomics or are looking for an interview partner? Please do not hesitate to contact me, you can reach me from Monday to Friday between 9 am and 6 pm.
+49 (0)30 94894423